CVS Faces Profit Slump but Shows Signs of Recovery 

CVS Health, one of the largest healthcare conglomerates in the United States, experienced a significant decline in its 2024 profits as its Aetna insurance division struggled with rising medical expenses. While the company’s net income fell nearly 50%, CVS exceeded Wall Street expectations in the fourth quarter, leading to a notable increase in its stock price. This article examines the reasons behind CVS’s financial struggles, the impact of increased medical spending, and the company’s outlook moving forward. 

The Numbers: A Tough Year for CVS 

According to its latest earnings report, CVS Health reported a net income of $4.6 billion in 2024, a steep drop from $8.4 billion in the previous year. This decline is primarily attributed to the surge in medical costs within its Aetna insurance division, particularly in Medicare Advantage (MA) and Medicaid plans. Despite these challenges, CVS managed to surpass Wall Street’s earnings and revenue expectations in the fourth quarter, prompting a nearly 10% increase in its stock during pre-market trading. 

Factors Behind the Decline 

• Increased Utilization of Healthcare Services: The aftermath of the COVID-19 pandemic led to a surge in healthcare utilization among seniors enrolled in Medicare Advantage plans. Many beneficiaries sought out medical services they had previously postponed, leading to higher-than-anticipated costs for insurers like Aetna. 

• Medicaid Enrollment and Cost Implications: The unwinding of the pandemic-era Medicaid continuous enrollment policy also played a crucial role. Starting in the spring of 2023, millions of previously enrolled individuals were removed from Medicaid coverage. This left behind a higher concentration of sicker beneficiaries with greater medical needs, further increasing costs for insurers. 

• Quality Ratings and Financial Adjustments: Compounding CVS’s struggles, the company faced challenges related to its Medicare Advantage quality ratings, which impacted reimbursement rates. Additionally, the company had to revise its financial projections multiple times throughout 2024, eventually withdrawing its earnings guidance altogether. This instability contributed to a sharp decline in investor confidence, with CVS stock trading significantly lower than the previous year. 

Signs of Stabilization 

Despite the financial turbulence, CVS executives express optimism about Aetna’s recovery. During a recent earnings call, CFO Tom Cowhey noted that while medical costs remained elevated, the trend in the fourth quarter was less severe than anticipated. CEO David Joyner, who took over leadership at CVS in October, echoed this sentiment, stating that the company had made “material progress” in stabilizing Aetna’s operations and reinforcing financial discipline. 

One of the key indicators of this progress is the company’s medical loss ratio (MLR)—a measure of how much of premium revenue is spent on patient care. Aetna’s MLR stood at 94.8% in the fourth quarter, compared to 88.5% in the same period the previous year. While this figure indicates high medical spending, it also suggests that the worst may be over for CVS. 

The Future of CVS’s Health Plans 

CVS reported a total enrollment of 27.1 million beneficiaries in its health plans for 2024, marking a 1.4 million increase from the prior year. However, executives anticipate a decline of over 1 million members in 2025 due to reductions in Affordable Care Act exchange plans and Medicare Advantage products. 

Joyner stated that the company expects to shrink its Medicare Advantage membership by a high single-digit percentage by the end of 2024. However, CVS is strategically focused on improving margins through more selective enrollment practices and enhanced star ratings for its Medicare plans. 

Performance in Other Business Segments 

• Health Services and Pharmacy Challenges: CVS’s health services division, which includes its Caremark pharmacy benefit manager, saw a modest decline in performance. Adjusted operating income for this segment decreased by 0.9%, totaling $7.2 billion for the full year. The company’s pharmacy and wellness unit also faced headwinds, with adjusted operating income falling 3.2% to $5.8 billion. This decline was driven by reduced store traffic and ongoing pressures related to pharmacy reimbursement. 

• Overall Revenue Growth: Despite the profit slump, CVS achieved revenue growth of over 4%, reporting a total of $372.8 billion in revenue for 2024. The company has projected adjusted earnings per share between $5.75 and $6 for 2025, suggesting confidence in its ability to rebound. 

Industry-Wide Trends 

CVS was not the only insurer to struggle with high medical costs in 2024. Humana, another major player in the health insurance sector, also reported that its profit more than halved due to increased spending on Medicare Advantage and Medicaid beneficiaries. This industry-wide trend highlights the financial strain that many payers faced as healthcare utilization returned to pre-pandemic levels. 

CVS Health’s financial performance in 2024 reflects the broader challenges facing the healthcare insurance industry. Rising medical costs, increased healthcare utilization, and regulatory changes in Medicaid have significantly impacted the company’s bottom line. However, with a strategic focus on financial discipline, improved quality ratings, and selective enrollment strategies, CVS executives remain optimistic about the future. 

The company’s ability to navigate these challenges will be critical in determining its long-term stability. While profits may have taken a hit, CVS’s revenue growth and better-than-expected fourth-quarter results suggest that the healthcare giant is on the path to recovery. As the industry continues to evolve, CVS’s next moves will be closely watched by investors and healthcare professionals alike.